|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||61.42 - 64.55|
|52 Week Range||22.49 - 92.57|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.00|
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa® technology has been used in research studies to detect the SARS-CoV-2 virus in serum/plasma, dried blood microsamples (DBS) and saliva samples obtained from polymerase chain reaction (PCR)+ COVID-19 patients. Published in Nature Communications, the research study of these technologies offers further evidence that non-invasive antigen detection in blood or saliva samples, including from asymptomatic and pre-symptomatic individuals, can serve as an important complement to testing of nasal and nasopharyngeal (NP) swab samples. In addition to the benefits of detecting COVID-19 during the pre-symptomatic window when transmissibility is known to be highest, measuring viral load in blood may be particularly relevant in the context of clinical studies, as an indicator of disease severity or progression, and potentially of therapeutic efficacy.
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology and various blood-based neurology biomarker assays were used by leading research teams to power 30 total oral and poster presentations at this year’s AD/PD 2021. The research efforts further underscore the vast utility of several blood-based biomarkers offered through Quanterix’ Neurology kits, including phosphorylated tau at threonine 181 (p-tau181), phosphorylated tau at threonine 231 (p-tau231), glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL). Notable findings showcased at the conference validate the potential of these markers as pre-screening tools prior to costly PET scans, as secondary endpoints of drug efficacy, and as important tools for the recruitment and disease stratification of pre-symptomatic patients into clinical trials through non-invasive methods.
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -3.33% and 3.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?